Viking Therapeutics (VKTX) Stock Forecast: What Could Drive It in 2026
Short answer
No one can reliably forecast VKTX's price, and Walnut does not publish targets. What is useful is the setup. For Viking Therapeutics, the drivers that could push it higher are real, and so are the risks that could weigh on it. Below is each side plus a framework to form your own view. This is descriptive, not a prediction or a recommendation.
What could drive Viking Therapeutics (VKTX) higher?
1. Lead obesity program (VK2735).
VK2735 is a dual GLP-1 and GIP receptor agonist for obesity, advancing in both injectable and oral forms. Strong early- and mid-stage weight-loss data put Viking among the most-watched challengers to Novo Nordisk and Eli Lilly in a very large and fast-growing obesity-drug market, and an oral option could be a meaningful differentiator if it succeeds.
2. Pipeline breadth in metabolic disease.
Beyond obesity, Viking is developing VK2809, a thyroid-hormone receptor beta agonist for NASH/MASH, a large liver-disease market, and VK0214 for the rare disease X-linked adrenoleukodystrophy. Multiple shots on goal in metabolic and endocrine disorders give the company more than a single binary outcome, though the obesity program dominates the story.
3. Strategic and acquisition optionality.
Successful obesity assets are highly sought after, and large pharma companies have been acquiring or partnering with GLP-1 developers. Viking's data and dual injectable/oral approach make it a frequently mentioned acquisition or partnership candidate, which is part of why the stock reacts sharply to both clinical data and deal speculation.
What could weigh on VKTX?
Viking is a clinical-stage biotech with no approved products and essentially no product revenue, so it is highly speculative and potentially binary. A single disappointing trial readout, safety signal, or regulatory setback for VK2735 could sharply reduce the stock's value. The obesity market is intensely competitive, dominated by Novo Nordisk and Eli Lilly with deep resources and manufacturing scale, and crowded with other entrants. Viking funds itself from cash and may need to raise more capital, diluting shareholders. Manufacturing, commercialization, and pricing all remain unproven. This is a high-risk position whose outcome depends on clinical and regulatory events outside investors' control.
How to think about a VKTX forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the VKTX guide and whether VKTX is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the VKTX outlook
The honest bottom line: Viking Therapeutics (VKTX)'s outlook hinges on whether its drivers (above) outpace its risks, and no one can promise which wins. Treat any VKTX forecast as a scenario, not a certainty, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around VKTX with Walnut
Use Viking Therapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Viking Therapeutics (VKTX)?
+
No one can reliably predict where VKTX will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Viking Therapeutics higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive VKTX higher?
+
The main growth drivers are Lead obesity program (VK2735); Pipeline breadth in metabolic disease; Strategic and acquisition optionality. Whether they play out is the real question, not a guaranteed path.
What are the risks to VKTX?
+
Viking is a clinical-stage biotech with no approved products and essentially no product revenue, so it is highly speculative and potentially binary. A single disappointing trial readout, safety signal, or regulatory setback for VK2735 could sharply reduce the stock's value. The obesity market is intensely competitive, dominated by Novo Nordisk and Eli Lilly with deep resources and manufacturing scale, and crowded with other entrants. Viking funds itself from cash and may need to raise more capital, diluting shareholders. Manufacturing, commercialization, and pricing all remain unproven. This is a high-risk position whose outcome depends on clinical and regulatory events outside investors' control.
Will VKTX stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Viking Therapeutics's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is VKTX a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the VKTX "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.